Abstract
There are several advantages of using the human pulmonary pathways for drug delivery. These include large absorption area, more rapid onset of therapeutic effect, reduced dose of bioactive delivery and lower side effects of therapy. Inhalable products should meet several criteria, in particular shape, surface roughness and particle size (approximately 1-5 µm, or 2-3 µm as optimum) to reach the deep region of human lungs (alveolus).In an attempt to produce such powders, supercritical fluid (SCF) technology has been proposed as an alternative to high energy consumptive yet popular mechanical methods such as milling. In this article, application of SCF technology for inhalable products manufacturing is briefly overviewed. Discussion focuses on the process development and formulation strategies to obtain improved product properties of specifically designed for pulmonary administration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: IOP Conference Series: Materials Science and Engineering
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
